Cynata Therapeutics Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kilian Kelly
- Full Time Employees
- - -
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 100 Cubitt Street Cremorne VIC Australia 3121
- IPO Date
- Oct 22, 2007
- Website
- cynata.com
- Similar Companies
- Business
- Cynata Therapeutics Limited (ASX: CYP) is a clinical-stage biotechnology company that develops and commercializes mesenchymal stem cell (MSC) therapies for the treatment of inflammatory diseases and critical illnesses. The company manufactures and supplies Cymerus, its proprietary iPSC-derived allogeneic MSC platform, which produces pure, off-the-shelf MSCs from induced pluripotent stem cells for scalable production; its lead product candidate CYP-004 advances through Phase 3 trials for graft-versus-host disease (GvHD), while CYP-002 and CYP-003 target acute respiratory distress syndrome (ARDS) and other respiratory conditions. Cynata offers research-grade Cymerus MSCs for preclinical studies and partners with contract manufacturers for commercial-scale production; additional pipeline assets include CYP-006 for solid organ transplant rejection and programs in osteoarthritis and sepsis [ from previous]. Founded in 2013 and headquartered in Melbourne, Australia, Cynata operates primarily in Australia with global clinical trial sites across North America, Europe, and Asia-Pacific, targeting hospitals, clinics, and biopharma partners in regenerative medicine. The company serves the biotechnology and healthcare sectors, focusing on immunology, pulmonology, and transplant medicine customer bases [ from previous]. In the past 1-2 years, Cynata completed patient recruitment for its CYP-004 Phase 3 trial in steroid-resistant acute GvHD in late 2024, positioning it for potential regulatory submission; it reported positive top-line data from the CYP-004 Phase 2 extension study confirming durable responses. Cynata secured a strategic manufacturing partnership with Lonza in 2024 to scale Cymerus production for commercialization; it also raised A$30 million through an institutional placement in mid-2025 to fund Phase 3 completion and pre-commercial activities. Recent expansions include initiation of investigator-led trials for Cymerus in liver disease and progression of preclinical assets into IND-enabling studies, alongside a strengthened cash position exceeding A$50 million as of Q3 2025 [ from previous].
Company News
Cynata Therapeutics Limited (CYYNF) Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results Transcript
Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript
Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis
Cynata Therapeutics (OTCMKTS:CYYNF) vs. Exelixis (NASDAQ:EXEL) Financial Survey
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript
Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript
Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts